TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS
6.1. Overview
6.2. Anti-inflammatory Biologics
6.3. NSAIDs
6.4. Others
7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION
7.1. Overview
7.2. Auto-immune Diseases
7.2.1. Rheumatoid Arthritis
7.2.2. Psoriasis
7.2.3. Multiple Sclerosis
7.2.4. Crohn's Disease
7.2.5. Ulcerative Colitis
7.2.6. Others
7.3. Respiratory Conditions
7.3.1. COPD
7.3.2. Asthma
7.4. Others
8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
8.1. Overview
8.2. Oral
8.3. Injection
8.4. Topical
8.5. Inhalation
9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
9.1. Overview
9.2. Hospital Pharmacies
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY REGION
10.1. Overview
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. France
10.2.3. UK
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Australia
10.3.6. Rest of Asia-Pacific
10.4. Rest of the World
10.4.1. Middle East
10.4.2. Africa
10.4.3. Latin America
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Global Anti-inflammatory Therapeutics Market,
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Global Anti-inflammatory Therapeutics Market,
11.7. Key Developments and Growth Strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales & Operating Income, 2023
11.8.2. Major Players R&D Expenditure. 2023
12. COMPANY PROFILES
12.1. AbbVie, Inc.
12.1.1. Company Overview
12.1.2. Financial Overview
12.1.3. Products Offered
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Merck & Co., Inc.
12.2.1. Company Overview
12.2.2. Financial Overview
12.2.3. Products Offered
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Johnson & Johnson Services, Inc.
12.3.1. Company Overview
12.3.2. Financial Overview
12.3.3. Products Offered
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Pfizer, Inc.
12.4.1. Company Overview
12.4.2. Financial Overview
12.4.3. Products Offered
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Novartis AG
12.5.1. Company Overview
12.5.2. Financial Overview
12.5.3. Products Offered
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. GlaxoSmithKline plc.
12.6.1. Company Overview
12.6.2. Financial Overview
12.6.3. Products Offered
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Amgen, Inc.
12.7.1. Company Overview
12.7.2. Financial Overview
12.7.3. Products Offered
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. F. HOFFMANN-LA ROCHE LTD.
12.8.1. Company Overview
12.8.2. Financial Overview
12.8.3. Products Offered
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. AstraZeneca
12.9.1. Company Overview
12.9.2. Financial Overview
12.9.3. Products Offered
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Sanofi
12.10.1. Company Overview
12.10.2. Financial Overview
12.10.3. Products Offered
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 6 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 9 NORTH AMERICA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 10 NORTH AMERICA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 11 US: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 12 US: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 13 US: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 14 US: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 15 CANADA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 16 CANADA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 17 CANADA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 18 CANADA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 3 EUROPE: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 4 EUROPE: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 5 GERMANY: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 6 GERMANY: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 7 GERMANY: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 8 GERMANY: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 9 FRANCE: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 10 FRANCE: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 11 FRANCE: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 12 FRANCE: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 13 ITALY: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 14 ITALY: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 15 ITALY: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 16 ITALY: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 17 SPAIN: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 18 SPAIN: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 19 SPAIN: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 20 SPAIN: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 21 UK: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 22 UK: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 23 UK: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 24 UK: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 25 REST OF EUROPE: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 26 REST OF EUROPE: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 27 REST OF EUROPE: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 28 REST OF EUROPE: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 29 ASIA-PACIFIC: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 30 ASIA-PACIFIC: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 31 ASIA-PACIFIC: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 32 ASIA-PACIFIC: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 33 JAPAN: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 34 JAPAN: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 35 JAPAN: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 36 JAPAN: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 37 CHINA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 38 CHINA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 39 CHINA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 40 CHINA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 41 INDIA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 42 INDIA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 43 INDIA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 44 INDIA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 45 AUSTRALIA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 46 AUSTRALIA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 47 AUSTRALIA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 48 AUSTRALIA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 49 SOUTH KOREA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 50 SOUTH KOREA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 51 SOUTH KOREA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 52 SOUTH KOREA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 53 REST OF ASIA-PACIFIC: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 54 REST OF ASIA-PACIFIC: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 55 REST OF ASIA-PACIFIC: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 56 REST OF ASIA-PACIFIC: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 57 REST OF THE WORLD: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 58 REST OF THE WORLD: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 59 REST OF THE WORLD: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 60 REST OF THE WORLD: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 61 MIDDLE EAST: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 62 MIDDLE EAST: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 63 MIDDLE EAST: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 64 MIDDLE EAST: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 65 AFRICA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 66 AFRICA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 67 AFRICA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 68 AFRICA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
TABLE 69 LATIN AMERICA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2032 (USD BILLION)
TABLE 70 LATIN AMERICA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 71 LATIN AMERICA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLION)
TABLE 72 LATIN AMERICA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET
FIGURE 4 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, SHARE (%), BY DRUG CLASS, 2023
FIGURE 5 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, SHARE (%), BY APPLICATION, 2023
FIGURE 6 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2023
FIGURE 7 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2023
FIGURE 8 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 NORTH AMERICA: ANTI-INFLAMMATORY THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 EUROPE: ANTI-INFLAMMATORY THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 ASIA-PACIFIC: ANTI-INFLAMMATORY THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 12 REST OF THE WORLD: ANTI-INFLAMMATORY THERAPEUTICS MARKET, SHARE (%), BY REGION, 2023
FIGURE 13 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 14 ABBVIE, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 ABBVIE, INC.: SWOT ANALYSIS
FIGURE 16 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 MERCK & CO., INC.: SWOT ANALYSIS
FIGURE 18 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS
FIGURE 20 PFIZER, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 PFIZER, INC.: SWOT ANALYSIS
FIGURE 22 NOVARTIS AG.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 NOVARTIS AG.: SWOT ANALYSIS
FIGURE 24 GLAXOSMITHKLINE PLC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 GLAXOSMITHKLINE PLC.: SWOT ANALYSIS
FIGURE 26 AMGEN, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 AMGEN, INC.: SWOT ANALYSIS
FIGURE 28 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
FIGURE 30 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 ASTRAZENECA: SWOT ANALYSIS
FIGURE 32 SANOFI: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 SANOFI: SWOT ANALYSIS
